ENTANasdaqPharmaceutical PreparationsFiscal year ends September 30
ENANTA PHARMACEUTICALS INC
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$11.41+0.31 (+2.79%)
Close on Oct 19, 2026
- Market cap
- $331.92M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
93.6%
27M of 29M shares
Institutional holders
122
13 new, 19 sold out
Net institutional buying
4M
In Q2 2026
Insider trades, 12 months
0 buys · 9 sales
Net sold $183.17K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Janus Henderson Group PLC | 3,494,068 | 12.10% | 13G (passive) | Oct 31, 2025 |
| Giauque, Nicolas | 2,816,862 | 9.80% | 13G (passive) amendment | Dec 31, 2025 |
| Dreyfuss, Philip D. | 2,418,202 | 8.30% | 13G (passive) amendment | Jun 30, 2026 |
| Linn, Michael G. | 2,108,262 | 9.90% | 13G (passive) amendment | Dec 31, 2024 |
| Deep Track Capital, LP | 1,956,867 | 6.78% | 13G (passive) amendment | Dec 31, 2025 |
| Jay R. Luly, Ph.D. | 1,703,616 | 7.70% | 13D (active) amendment | Feb 12, 2025 |
| BlackRock, Inc. | 1,673,483 | 7.80% | 13G (passive) amendment | Mar 31, 2025 |
| Millennium Management LLC | 1,382,273 | 6.50% | 13G (passive) | Jan 14, 2025 |
| Krensavage Asset Management, LLC | 1,086,024 | 5.10% | 13G (passive) | Feb 22, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ENTA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Jupiter Topco LLC | 3,654,920 | 12.55% | $53.25M | New | 0.02% |
| BlackRock, Inc. | 3,244,448 | 11.14% | $47.30M | +140,680 | 0.00% |
| Krensavage Asset Management, LLC | 2,866,138 | 9.84% | $41.79K | – | 15.88% |
| Farallon Capital Management LLC | 2,418,202 | 8.30% | $35.26M | −453,660 | 0.16% |
| Deep Track Capital, LP | 1,444,167 | 4.96% | $21.06M | −512,700 | 0.31% |
| ADAR1 Capital Management, LLC | 1,344,510 | 4.62% | $19.60M | +1,293,153 | 0.90% |
| Vanguard Capital Management LLC | 1,211,769 | 4.16% | $17.67M | +33,720 | 0.00% |
| Spruce Street Capital LP | 1,088,731 | 3.74% | $15.87M | +156,133 | 3.11% |
| Acadian Asset Management LLC | 1,078,317 | 3.70% | $15.71K | +198,294 | 0.02% |
| Vanguard Portfolio Management LLC | 1,011,494 | 3.47% | $14.75M | +62,590 | 0.00% |
| Geode Capital Management, LLC | 776,634 | 2.67% | $11.33M | +51,573 | 0.00% |
| Millennium Management LLC | 643,967 | 2.21% | $9.39M | −238,130 | 0.00% |
| State Street Corp | 576,117 | 1.98% | $8.40M | +14,011 | 0.00% |
| Renaissance Technologies LLC | 557,600 | 1.91% | $8.13M | −107,658 | 0.01% |
| Hillsdale Investment Management Inc. | 468,000 | 1.61% | $6.82M | +32,490 | 0.16% |
| Goldman Sachs Group Inc | 464,649 | 1.60% | $6.77M | +199,561 | 0.00% |
| Morgan Stanley | 315,729 | 1.08% | $4.60M | +6,218 | 0.00% |
| Charles Schwab Investment Management Inc | 301,151 | 1.03% | $4.39M | +6,180 | 0.00% |
| Dimensional Fund Advisors LP | 282,682 | 0.97% | $4.12M | +79,430 | 0.00% |
| Northern Trust Corp | 259,696 | 0.89% | $3.79M | +18,728 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 122 | 27M | 93.6% | 13 / 47 | 38 / 19 | 7M | 2M |
| Q1 2026 | 133 | 27M | 91.9% | 24 / 49 | 33 / 21 | 4M | 2M |
| Q4 2025 | 132 | 26M | 90.6% | 36 / 45 | 28 / 24 | 10M | 3M |
| Q3 2025 | 122 | 19M | 65.6% | 25 / 33 | 42 / 11 | 3M | 3M |
| Q2 2025 | 108 | 18M | 63.3% | 15 / 34 | 43 / 17 | 1M | 1M |
| Q1 2025 | 110 | 19M | 64.0% | 20 / 36 | 38 / 17 | 2M | 3M |
| Q4 2024 | 108 | 20M | 68.4% | 23 / 35 | 31 / 27 | 3M | 5M |
| Q3 2024 | 112 | 21M | 73.7% | 18 / 38 | 31 / 6 | 4M | 3M |
| Q2 2024 | 101 | 22M | 76.5% | 11 / 33 | 44 / 18 | 1M | 6M |
| Q1 2024 | 108 | 27M | 91.5% | 16 / 26 | 51 / 14 | 8M | 3M |
| Q4 2023 | 106 | 21M | 73.3% | 15 / 41 | 41 / 42 | 5M | 3M |
| Q3 2023 | 133 | 20M | 69.2% | 25 / 45 | 45 / 25 | 5M | 5M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of ENTA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 877,120 | 3.01% | $12.79M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 731,781 | 2.51% | $10.67M | 0.01% | Jun 30, 2026 |
| BlackRock Health Sciences Opportunities Portfolio | 492,001 | 1.69% | $6.47M | 0.11% | May 29, 2026 |
| Fidelity Small Cap Index Fund | 307,927 | 1.06% | $3.88M | 0.01% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 301,261 | 1.03% | $4.39M | 0.00% | Jun 30, 2026 |
| Vanguard Strategic Small-Cap Equity Fund | 280,927 | 0.96% | $4.10M | 0.13% | Jun 30, 2026 |
| iShares Biotechnology ETF | 194,701 | 0.67% | $2.84M | 0.03% | Jun 30, 2026 |
| Vanguard Strategic Equity Fund | 180,741 | 0.62% | $2.64M | 0.02% | Jun 30, 2026 |
| Vanguard Explorer Fund | 140,620 | 0.48% | $1.77M | 0.01% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 139,841 | 0.48% | $1.84M | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 139,763 | 0.48% | $1.84M | 0.01% | May 31, 2026 |
| iShares Russell 2000 Value ETF | 137,426 | 0.47% | $2.00M | 0.01% | Jun 30, 2026 |
| Small Company Growth Portfolio | 136,247 | 0.47% | $1.99M | 0.12% | Jun 30, 2026 |
| Schwab U.S. Small-Cap ETF | 128,383 | 0.44% | $1.69M | 0.01% | May 31, 2026 |
| iShares Russell 2000 Growth ETF | 123,846 | 0.43% | $1.81M | 0.01% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jay R. Luly | President and CEO, Director | 871,871 | 2.99% | Feb 13, 2026 |
| Scott T. Rottinghaus | Chief Medical Officer | 23,787 | 0.08% | Aug 10, 2026 |
| Yat Sun Or | Chief Scientific Officer | 374,854 | 1.29% | Feb 13, 2026 |
| Brendan Luu | Chief Business Officer | 44,891 | 0.15% | Feb 13, 2026 |
| Tara Lynn Kieffer | Chief Product Strategy Officer | 32,195 | 0.11% | Feb 13, 2026 |
| Matthew Paul Kowalsky | Chief Legal Officer | 3,591 | 0.01% | Feb 13, 2026 |
| Harry R. Trout III | See Remarks | 16,348 | 0.06% | Dec 5, 2025 |
| Kathleen S. Capps | See Remarks | 8,377 | 0.03% | Dec 5, 2025 |
| Paul J. Mellett | Chief Fin. & Admin Officer | 99,210 | 0.34% | Feb 14, 2025 |
| Lesley Russell | Director | – | – | Mar 13, 2026 |
| Yujiro S. Hata | Director | – | – | Mar 13, 2026 |
| Kristine Peterson | Director | – | – | Mar 13, 2026 |
| Mark G. Foletta | Director | – | – | Mar 13, 2026 |
| Bruce L. A. Carter | Director | 0 | – | Mar 13, 2026 |
| Terry Vance | Director | 5,800 | 0.02% | Mar 13, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Scott T. Rottinghaus Chief Medical Officer | Aug 8, 2026 | Tax withholding | −1,467 | $13.34 | $19.57K | 23,787 |
| Yat Sun Or Chief Scientific Officer | Feb 12, 2026 | Tax withholding | −3,413 | $14.25 | $48.64K | 374,854 |
| Yat Sun Or Chief Scientific Officer | Feb 12, 2026 | Award | +1,650 | – | – | 373,042 |
| Yat Sun Or Chief Scientific Officer | Feb 12, 2026 | Award | +5,225 | – | – | 378,267 |
| Jay R. Luly President and CEO, Director | Feb 12, 2026 | Tax withholding | −6,155 | $14.25 | $87.71K | 871,871 |
| Jay R. Luly President and CEO, Director | Feb 12, 2026 | Award | +15,200 | – | – | 878,026 |
| Jay R. Luly President and CEO, Director | Feb 12, 2026 | Award | +4,800 | – | – | 862,826 |
| Tara Lynn Kieffer Chief Product Strategy Officer | Feb 12, 2026 | Award | +1,575 | – | – | 32,195 |
| Tara Lynn Kieffer Chief Product Strategy Officer | Feb 12, 2026 | Award | +4,987 | – | – | 37,182 |
| Tara Lynn Kieffer Chief Product Strategy Officer | Feb 12, 2026 | Tax withholding | −3,257 | $14.25 | $46.41K | 33,925 |
| Matthew Paul Kowalsky Chief Legal Officer | Feb 12, 2026 | Tax withholding | −1,902 | $14.25 | $27.10K | 3,591 |
| Matthew Paul Kowalsky Chief Legal Officer | Feb 12, 2026 | Award | +1,318 | – | – | 1,318 |
| Matthew Paul Kowalsky Chief Legal Officer | Feb 12, 2026 | Award | +4,175 | – | – | 5,493 |
| Brendan Luu Chief Business Officer | Feb 12, 2026 | Award | +4,987 | – | – | 44,891 |
| Brendan Luu Chief Business Officer | Feb 12, 2026 | Award | +1,575 | – | – | 39,904 |
| Brendan Luu Chief Business Officer | Feb 12, 2026 | Tax withholding | −3,257 | $14.25 | $46.41K | 41,634 |
| Scott T. Rottinghaus Chief Medical Officer | Feb 12, 2026 | Award | +1,650 | – | – | 23,442 |
| Scott T. Rottinghaus Chief Medical Officer | Feb 12, 2026 | Tax withholding | −3,413 | $14.25 | $48.64K | 25,254 |
| Scott T. Rottinghaus Chief Medical Officer | Feb 12, 2026 | Award | +5,225 | – | – | 28,667 |
| Harry R. Trout III See Remarks | Dec 5, 2025 | Sale | −542 | $14.23 | $7.71K | 16,348 |
| Tara Lynn Kieffer Chief Product Strategy Officer | Dec 5, 2025 | Sale | −2,106 | $14.23 | $29.97K | 30,620 |
| Jay R. Luly President and CEO, Director | Dec 5, 2025 | Sale | −4,743 | $14.23 | $67.49K | 858,026 |
| Brendan Luu Chief Business Officer | Dec 5, 2025 | Sale | −1,394 | $14.23 | $19.84K | 38,329 |
| Scott T. Rottinghaus Chief Medical Officer | Dec 5, 2025 | Sale | −798 | $14.23 | $11.36K | 21,792 |
| Yat Sun Or Chief Scientific Officer | Dec 5, 2025 | Sale | −2,390 | $14.23 | $34.01K | 371,392 |
| Kathleen S. Capps See Remarks | Dec 5, 2025 | Sale | −323 | $14.23 | $4.60K | 8,377 |
| Kathleen S. Capps See Remarks | Dec 2, 2025 | Sale | −207 | $13.96 | $2.89K | 8,700 |
| Harry R. Trout III See Remarks | Dec 2, 2025 | Sale | −380 | $13.96 | $5.30K | 16,890 |
| Jay R. Luly President and CEO, Director | Dec 1, 2025 | Tax withholding | −1,885 | $14.12 | $26.62K | 862,769 |
| Kathleen S. Capps See Remarks | Dec 1, 2025 | Tax withholding | −85 | $14.12 | $1.20K | 8,907 |
| Brendan Luu Chief Business Officer | Dec 1, 2025 | Tax withholding | −498 | $14.12 | $7.03K | 39,723 |
| Yat Sun Or Chief Scientific Officer | Dec 1, 2025 | Tax withholding | −753 | $14.12 | $10.63K | 373,782 |
| Tara Lynn Kieffer Chief Product Strategy Officer | Dec 1, 2025 | Tax withholding | −753 | $14.12 | $10.63K | 32,726 |
| Harry R. Trout III See Remarks | Dec 1, 2025 | Tax withholding | −105 | $14.12 | $1.48K | 17,270 |
| Kathleen S. Capps See Remarks | Nov 25, 2025 | Award | +3,163 | – | – | 8,992 |
| Harry R. Trout III See Remarks | Nov 25, 2025 | Award | +6,463 | – | – | 17,375 |
| Scott T. Rottinghaus Chief Medical Officer | Aug 8, 2025 | Tax withholding | −2,217 | $6.99 | $15.50K | 22,590 |
| Jay R. Luly President and CEO, Director | Feb 12, 2025 | Tax withholding | −7,484 | $5.59 | $41.84K | 864,654 |
| Jay R. Luly President and CEO, Director | Feb 12, 2025 | Award | +25,500 | – | – | 872,138 |
| Tara Lynn Kieffer Chief Product Strategy Officer | Feb 12, 2025 | Tax withholding | −3,326 | $5.59 | $18.59K | 33,479 |
| Tara Lynn Kieffer Chief Product Strategy Officer | Feb 12, 2025 | Award | +7,500 | – | – | 36,805 |
| Scott T. Rottinghaus Chief Medical Officer | Feb 12, 2025 | Tax withholding | −2,861 | $5.59 | $15.99K | 24,807 |
| Scott T. Rottinghaus Chief Medical Officer | Feb 12, 2025 | Award | +9,750 | – | – | 27,668 |
| Brendan Luu Chief Business Officer | Feb 12, 2025 | Tax withholding | −3,326 | $5.59 | $18.59K | 40,221 |
| Brendan Luu Chief Business Officer | Feb 12, 2025 | Award | +7,500 | – | – | 43,547 |
| Paul J. Mellett Chief Fin. & Admin Officer | Feb 12, 2025 | Award | +7,500 | – | – | 99,210 |
| Paul J. Mellett Chief Fin. & Admin Officer | Feb 12, 2025 | Tax withholding | −3,326 | $5.59 | $18.59K | 95,884 |
| Yat Sun Or Chief Scientific Officer | Feb 12, 2025 | Award | +9,750 | – | – | 378,859 |
| Yat Sun Or Chief Scientific Officer | Feb 12, 2025 | Tax withholding | −4,324 | $5.59 | $24.17K | 374,535 |
| Jay R. Luly President and CEO, Director | Feb 12, 2025 | Buy | +45,000 | $5.69 | $256.05K | 846,638 |
| Tara Lynn Kieffer Chief Product Strategy Officer | Dec 6, 2024 | Sale(10b5-1 plan) | −2,283 | $8.06 | $18.40K | 29,305 |
| Jay R. Luly President and CEO, Director | Dec 6, 2024 | Sale(10b5-1 plan) | −5,142 | $8.06 | $41.44K | 801,638 |
| Paul J. Mellett Chief Fin. & Admin Officer | Dec 6, 2024 | Sale(10b5-1 plan) | −2,591 | $8.06 | $20.88K | 91,710 |
| Yat Sun Or Chief Scientific Officer | Dec 6, 2024 | Sale(10b5-1 plan) | −2,591 | $8.06 | $20.88K | 369,109 |
| Scott T. Rottinghaus Chief Medical Officer | Dec 6, 2024 | Sale(10b5-1 plan) | −866 | $8.06 | $6.98K | 17,918 |
| Brendan Luu Chief Business Officer | Dec 6, 2024 | Sale(10b5-1 plan) | −2,283 | $8.06 | $18.40K | 36,047 |
| Brendan Luu Chief Business Officer | Dec 1, 2024 | Tax withholding | −753 | $8.60 | $6.48K | 38,330 |
| Yat Sun Or Chief Scientific Officer | Dec 1, 2024 | Tax withholding | −1,595 | $8.60 | $13.72K | 371,700 |
| Jay R. Luly President and CEO, Director | Dec 1, 2024 | Tax withholding | −3,829 | $8.60 | $32.93K | 806,780 |
| Paul J. Mellett Chief Fin. & Admin Officer | Dec 1, 2024 | Tax withholding | −1,595 | $8.60 | $13.72K | 94,301 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Jay R. Luly Officer, Director | Dec 5, 2025 | 4,743 | $67.54K | Dec 5, 2025 | Restricted Stock Unit Vesting |
| T. Rottinghaus Scott Officer | Jul 11, 2024 | 11,945 | $178.70K | Jul 11, 2024 | RSU Release |
| Lynn Kieffer Tara Officer | Jun 17, 2024 | 7,266 | $92.35K | Jun 17, 2024 | PSU Release |
| Terry Vance Director | Dec 12, 2023 | 15,295 | $138.57K | Dec 13, 2023 | Initial Public Offering |